Hostname: page-component-7c8c6479df-5xszh Total loading time: 0 Render date: 2024-03-28T18:15:52.828Z Has data issue: false hasContentIssue false

Prevalence of Obesity in Patients Receiving Depot Antipsychotics

Published online by Cambridge University Press:  02 January 2018

T. Silverstone
Affiliation:
Medical College of St Bartholomew's Hospital, London
Glenyss Smith
Affiliation:
Medical College of St Bartholomew's Hospital, London
Elizabeth Goodall*
Affiliation:
Medical College of St Bartholomew's Hospital, London
*
Academic Unit of Human Psychopharmacology, St John's Wing, Homerton Hospital, Homerton Row, London E9 6SR

Abstract

Antipsychotic drugs have long been noted to cause pronounced weight gain, and drug-induced obesity can assume major clinical importance in long-term medication in the management of chronic schizophrenia. Obesity is associated with increased morbidity and may reduce compliance, leading to a return of psychotic symptoms. In a survey of 226 patients attending depot neuroleptic clinics in one inner London borough, it was found that the prevalence of clinically relevant obesity was four times that in the general population.

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1988 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Amdisen, A. (1964) Drug produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Danish Medical Bulletin, 11, 182189.Google ScholarPubMed
Creese, I., Burt, D. R. & Snyder, S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrcnic drugs. Science, 192, 481483.CrossRefGoogle ScholarPubMed
Garrow, J. S. (1981) Treat Obesity Seriously. Edinburgh: Churchill Livingstone.Google Scholar
Harris, E. & Eth, S. (1981) Weight gain during neuroleptic treatment. International Journal of Nursing Studies, 18, 171175.CrossRefGoogle ScholarPubMed
Jacobs, D. (1986) The dextroamphetamine response in human subjects: a psychological, psychophysiological and neuroendocrine study. MD Thesis, University of Adelaide, South Australia.Google Scholar
Johnson, D. A. W. & Breen, M. (1979) Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatrica Scandinavica, 59, 525528.CrossRefGoogle ScholarPubMed
Knight, I. (1984) The Heights and Weights of Adults in Great Britain (OPCS). London: HMSO.Google Scholar
Korsgaard, S. & Skausig, O. B. (1979) Increase in weight after treatment with depot neuroleptics. Acta Psychiatrica Scandinavica, 59, 139144.CrossRefGoogle ScholarPubMed
Marriott, P., Hansa, M. & Hiep, A. (1981) Depot fluphenazine maintenance treatment and associated weight changes. Comprehensive Psychiatry, 22, 320325.CrossRefGoogle ScholarPubMed
Office of Population Censuses and Surveys (1981) Adult heights and weights survey. OPCS Monitor, Ref. SS 81/1.Google Scholar
Robinson, R. G., McHugh, P. R. & Folstein, M. F. (1975) Measurement of appetite disturbances in psychiatric disorders. Journal of Psychiatric Research, 12, 5968.CrossRefGoogle ScholarPubMed
Royal College of Physicians (1983) Obesity. Journal of the Royal College of Physicians of London, 17, 665.Google Scholar
Silverstone, T., Fincham, J., Wells, B. & Kyriakides, M. (1980) The effect of the dopamine receptor blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man. Neuropharmacology, 19, 12351237.CrossRefGoogle ScholarPubMed
Wistedt, B., Persson, T. & Hellbom, E. (1984) A clinical double blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research, 35, 804814.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.